IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter-randomised, double blind, placebo-controlled trial. Neurology1993; 43: 655–661.
2.
JacobsLDCookfairDLRudickRA. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol1996; 39: 285–294.
3.
PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomized double-blind placebo controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet1998; 352: 1498–1504.
4.
JohnsonKPBrooksBRCohenJA. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology1998; 50: 701–708.
5.
CohenJABarkhofFComiG.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362: 402–415.
6.
KapposLRadueEWO’ConnorP.; FREEDOMS Study Group. Aplacebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362: 387–401.
